Table 2.
Gene | HGVS Nomenclature | Molecular consequence | Number of participants | PHx Cancer | FHx PDAC |
---|---|---|---|---|---|
ATM | c.1444A > C | VUS | n = 1 Female | Dx 47 breast | 1FDR;1SDR |
BRCA1 | c.14C > T a | VUS | n = 1 Femalea | – | 2FDR; 1SDR |
c.2475delC | Pathogenic; Frameshift/Truncating mutation | n = 1 Femaleb | Dx 42/54 breast; Dx 48 fallopian tube | 1FDR | |
BRCA2 | c.250C > T | Pathogenic; Nonsense | n = 1 Female | Dx 49 breast | 1FDR |
c.750_753del4 | Pathogenic; Deletion | n = 1 Female | – | 2SDR | |
c.971G > Ca | VUS | n = 1 Femalea | – | 2FDR; 1SDR | |
c.2808_2811del | Pathogenic; Frameshift/Truncating mutation | n = 1 Male (at 50% risk) | – | 2FDR (siblings) | |
c.3847_3848delGT | Pathogenic; Frameshift/Truncating mutation | n = 1 Male | – | 2FDR | |
c.4405_4409del | Pathogenic; Frameshift/Truncating mutation | n = 1 Female | Dx 53 follicular thyroid; Dx 63 breast | 1FDR; 1TDR | |
c.4478_4481del | Pathogenic; Frameshift/Truncating mutation | n = 1 Female | Dx 37/49 breast | 1FDR | |
c.4544del | Pathogenic; Frameshift/Truncating mutation | n = 1 Male | Dx 42/43 melanoma | 1FDR | |
c.4587dupG | Pathogenic; Frameshift/Truncating mutation | n = 1 Male | – | 5FDR | |
c.5238dup | Pathogenic; Nonsense | Kindred 1 | |||
n = 1 Female | Dx 57/58 breast | 1FDR; 1SDR | |||
Kindred 2 | |||||
n = 1 Femalec | Dx 55 PDAC on study; Dx56 CRC | 1FDR | |||
n = 1 Female | - | 2FDR | |||
n = 1 Male | - | 2FDR | |||
c.5303-5304delTT | Pathogenic; Frameshift/Truncating mutation | n = 1 Female | – | 1FDR | |
c.5681dupA | Pathogenic; Truncating mutation | Kindred 1 | |||
n = 1 Femalec | Dx 48 PDAC on study; Dx49 gastric | 1FDR; 1SDR | |||
n = 2 Males | - | 2FDRc; 1SDR | |||
n = 1 Female | - | 1FDR; 2SDRc | |||
n = 1 Female (at 50% risk) | - | 2FDRc; 1SDR | |||
c.5682C > G | Pathogenic; Truncating mutation | n = 1 Male | Dx 58 liver | 1FDR | |
c.5946del (Jewish founder) | Pathogenic; Frameshift/Truncating mutation | Kindred 1 | |||
n = 1 male | Dx 64 prostate | 1FDR | |||
n = 1 female | - | 1FDR | |||
n = 1 female | - | 1SDR | |||
Kindred 2 | |||||
n = 1 female | Dx 45 DCIS | 1SDR | |||
Kindred 3 | |||||
n = 1 Femaleb | Dx 42/54 breast; Dx 48 fallopian tube | 1FDR | |||
Kindred 4 | |||||
n = 1 Female | - | 1SDR; 3TDR | |||
n = 1 Female | Dx 65 ovarian | 1SDR; 3TDR | |||
Kindred 5 | |||||
n = 1 Male | - | 1FDR | |||
Kindred 6 | |||||
n = 1 female | - | 1TDR | |||
n = 2 males | - | 1SDR | |||
Kindred 7 | |||||
n = 1 male | Dx 55 brain; Dx 60 prostate | 1FDR; 1SDR | |||
Kindred 8 | |||||
n = 1 Male | - | 1FDR | |||
n = 1 Female | Dx 34 CRC | 1FDR | |||
c.6405_6409delCTTAA | Pathogenic; Frameshift/Truncating mutation | n = 1 Male | – | 1FDR | |
c.7505G > A | VUS | n = 1 Female | Dx 32 breast | 1FDR; 1SDR | |
c.7757G > A | Pathogenic; Nonsense | n = 1 Male | – | 1FDR | |
c. 7806-2A > G | Pathogenic; Splice acceptor | n = 1 Male | – | 1FDR | |
c.7976 + 5G > C | Likely pathogenic; Splicing disruptor | n = 1 Female | – | 1SDR | |
c.7977-1G > C | Pathogenic; Splice acceptor | n = 1 Male | – | 1SDR | |
c.7988A > T | Pathogenic; Missense | n = 1 Female | Dx 49 breast | 1FDR | |
c.8167G > C | Pathogenic; Missense | n = 1 Female | Dx 39 breast | 1FDR | |
c.8575del | Pathogenic; Frameshift/Truncating mutation | Kindred 1 | |||
n = 1 Male | Dx 75 RCC | 1FDR | |||
n = 1 Female | Dx 62 breast | 1FDR | |||
n = 1 Male | - | 1SDR | |||
Kindred 2 | |||||
n = 1 Female | - | 1FDR | |||
c.9154C > T | Pathogenic; Missense | n = 1 Female | – | 1FDR; 1SDR | |
c.9294C > G | Pathogenic; Truncating mutation | Kindred 1 | |||
n = 1 Male | - | 1FDR | |||
n = 1 Female | Dx 46 breast | 1FDR | |||
c.9371A > T | Pathogenic; Missense | n = 1 Female | Dx 44 breast | 1SDR | |
c.9924C > G | Pathogenic; Truncating mutation | Kindred 1 | |||
n = 1 Female | Dx 43 breast | 2TDR | |||
n = 1 Female | Dx 33/40 breast | 1SDR; 1TDR | |||
Exon 14–16 deletion | Pathogenic; Deletion | n = 1 Male | – | 1FDR | |
CDKN2A | c.47 T > G p.(Leu16Arg) | Pathogenic; Missense | n = 1 Female | Dx 45 melanoma | 1FDR; 1SDR |
c.95 T > C | Pathogenic; Missense | Kindred 1 | |||
n = 1 Female | - | 3FDR | |||
Kindred 2 | |||||
N = 1 Male n = 1 |
Dx 30 melanoma | 2SDR | |||
Female | Dx 21 melanoma | 2SDR | |||
n = 1 Female | - | 1FDR; 1SDR | |||
MLH1 | c.1758delC | Pathogenic; Truncating mutation | n = 1 Male | Dx 37 BCC; Dx 40 CRC | 1FDR |
PALB2 | c.487_488del | Pathogenic; Frameshift/Truncating mutation | Kindred 1 | ||
n = 1 Female | Dx 49 breast | 1FDR; 2SDR | |||
n = 1 Female (at 50% risk) | - | 1FDR; 2SDR | |||
n = 1 Male | - | 1FDR; 2SDR | |||
c.2257C > T | Pathogenic; Nonsense | Kindred 1 | |||
n = 1 Female | - | 1FDR; 1SDR | |||
Kindred 2 | |||||
n = 1 Female | - | 1FDR | |||
c.3113G > A | Pathogenic; Nonsense | n = 1 Male | Dx 40 melanoma | 1FDR | |
n = 1 Female | Dx 52 BCC | ||||
c.3209 T > C | VUS | n = 1 Female | Dx 55 breast | 2FDR | |
c.3362delG | Pathogenic; Frameshift | Kindred 1 | |||
n = 1 Male | - | 1SDR | |||
n = 1 Female | Dx 28 melanoma; Dx 42 breast; Dx 55 SCC/BCC | 1FDR | |||
c.3426_3429del | Pathogenic; Frameshift | n = 1 Female | – | 1FDR; 1SDR | |
PRSS1 | c.86A > C | Pathogenic; Missense | n = 1 Male | Dx chronic pancreatitis | Nil PDAC; 1FDR chronic pancreatitis |
c.86A > T | Pathogenic; Missense | n = 1 Female | Dx chronic pancreatitis | 1FDR; 2SDR | |
STK11 | c.179dup | Pathogenic, Nonsense | n = 1 Male | – | De novo PV |
Exon 2–9 deletion | Pathogenic; Deletion | n = 1 Female | – | De novo PV |
FDR first-degree relative; SDR second-degree relative; TDR third-degree relative; CRC colorectal cancer; DCIS ductal carcinoma in situ; BCC basal cell carcinoma; SCC squamous cell carcinoma; RCC renal cell carcinoma. a same participant; both VUS identified in affected FDR; b same participant; c diagnosed PDAC on study